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Abstract. In Croatia, colorectal cancer mortality rates in 
males are the third highest in Europe, after Hungary and 
Slovakia. The results for females rank Croatia in second 
place after Hungary. According to previous studies, the loss 
of E-cadherin expression and the higher expression of neural 
precursor cell-expressed developmentally downregulated 9 
(NEDD9) are associated with a worse prognosis. The aim of 
the present study was to analyze the immunohistochemical 
expression of NEDD9 and E-cadherin as markers of metastatic 
potential using a tissue microarray. This retrospective study 
included 40 previously untreated patients, including 23 males 
and 17 females with a median age of 64.5 years (range 38-84), 
with colorectal cancer and synchronous liver metastases that 
underwent simultaneous colorectal and hepatic resection 
between January 1st 2006 and December 31st 2013, in the 
Clinical Hospital Center Sestre Milosrdnice (Zagreb, Croatia). 
The most frequent tumor stage was T3, while the most frequent 
nodal stage was N1. Microvascular invasion was present in 
37.5% of patients, while perineural invasion was observed in 
30% of patients. The immunohistochemical staining index of 
E-cadherin was highly positive in 87.5% samples of colorectal 
cancer, 67.7% of lymph nodes and 77.5% of liver metastases. 
In the primary tumor, highly positive NEDD9 expression 
was identified in 22.5% of patients. In lymph nodes, it was 
identified in 35.5% of patients, while in the liver, it was identi-
fied in 30% of patients. Significant positive correlations were 
observed between the percentage of positive lymph nodes 
and the immunohistochemical staining index of E-cadherin 
(ρ=0.372; P=0.039) and NEDD9 (ρ=0.451; P=0.011) in lymph 
nodes. After the conclusion of the study, 55% of the patients 
succumbed. No significant differences in survival rates were 
identified regarding the expression of E‑cadherin and NEDD9 
in the primary tumor, metastatic lymph nodes and liver metas-
tases. Due to the small sample size and the negative results 
obtained, further research is required to implement these 
parameters as prognostic factors.
Introduction
Colorectal cancer (CRC) is the second most frequently diag-
nosed cancer and the third leading cause of cancer-related 
death in Croatia. According to the data obtained from the 
Croatian National Cancer Registry for 2015, there were 
1,890 new cases in the male population, and 1,339 in the 
female population. During the same year, 2,056 people 
succumbed to CRC (1). Despite the existence of the Croatian 
national colorectal screening program, the trends in the rates 
of incidence and mortality still display an increase in CRC. At 
the time of primary diagnosis, 41% of patients have positive 
regional lymph nodes (LN) and 14% of patients have evidence 
of distant metastases (1).
Approximately 75-80% of all CRC cases are sporadic, while 
approximately 20% may be familial, due to low-penetrance 
genes without a clear pattern. Only 5% of CRCs are clearly 
inherited (familial adenomatous polyposis, Lynch syndrome, 
MUTYH-associated polyposis, Peutz-Jeghers syndrome, 
juvenile polyposis, Cowden syndrome and serrated polyposis). 
Most cases of hereditary CRC have an autosomal dominant 
inheritance pattern (except MUTYH-associated polyposis) (2). 
Relevant risk factors are as follows: Age (>50 years), lifestyle 
(high‑fat, low‑fiber‑diet, obesity, physical inactivity, smoking 
and alcohol consumption), colorectal adenoma, inflammatory 
bowel disease (Crohn's disease and ulcerative colitis), and a 
family history of CRC. Primary tumor location is an important 
prognostic factor and has an effect on clinical presentation. 
The initial symptoms of left-sided CRC tumors are a change 
in bowel habits and bleeding; as these symptoms are more 
palpable, therefore they are identified, and CRC is diagnosed, 
at an earlier stage. Right-sided CRC tumors grow unnoticed 
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until they are large, and symptoms are unspecific: Abdominal 
pain, vomiting and anemia.
Diagnosis should be confirmed with an endoscopically‑guided 
biopsy. Diagnostic workup should include a complete blood 
count, liver and renal function tests, carcinoembryonic antigen 
and cancer antigen 19-9, multi-slice computed tomography of 
the chest, abdomen and pelvis, and magnetic resonance imaging 
of the pelvis (for rectal cancer). A multidisciplinary team 
approach insures that patients receive the best possible care. The 
pathology report should include the histology type, degree of 
differentiation, depth of bowel wall infiltration (T status), affected 
and examined LNs (N status) and presence of lymphovascular 
or perineural invasion (PNI). Clinical and pathological staging 
should be performed according to the latest edition of the 
International Union Against Cancer (UICC)/American Joint 
Committee of Cancer (AJCC) tumor-node-metastasis (TNM) 
classification for CRC. Clinical outcomes have improved 
dramatically over the past 15 years due to the availability of 
more active chemotherapeutic agents, and anti-VEGF and 
anti-EGFR targeted agents, but also due to the development of 
different surgical approaches (including colon‑first, liver‑first, 
two-step or simultaneous resection) and the possibilities for the 
local ablative treatment of liver, lung and peritoneal metastases 
(including chemoembolization, radioembolization, stereotactic 
radiotherapy and radiofrequency ablation). The median survival 
rate for patients with metastatic CRC is currently about 
30 months. This improvement is achieved due to continuum of 
care, which includes different possible combinations of patient 
treatment i.e., combinations of drugs and different time-frame 
of therapy. The latest findings are focused on microsatellite 
instability high CRC, which may be sensitive to programmed 
cell death protein 1 (PD-1) inhibitors.
It is critical to identify the molecular markers of CRC, 
which can be used to monitor or predict the progression and 
prognosis of patients with CRC, and to investigate these poten-
tial biomarkers as therapeutic targets.
A crucial role in the progression and aggressiveness of CRC 
is attributed to epithelial-mesenchymal transition (EMT), a 
reversible developmental process that includes the dissolution 
of adherens junctions and loss of apicobasolateral polarity, 
resulting in the formation of migratory mesenchymal cells with 
invasive properties. During the EMT process, cancer cells lose 
the expression of cellular adhesion proteins such as epithelial 
(E-) cadherin and γ-catenin (3). E-cadherin is a member of 
the large cadherins family of calcium-dependent cell adhe-
sion proteins. This single-pass transmembrane glycoprotein, 
encoded by the CDH1 gene on chromosome 16q22.1, has a 
molecular weight of 120 kDa. The mature protein comprises 
a long extracellular domain with five E-cadherin repeats 
(EC1-5), a short transmembrane domain, and a cytoplasmic 
domain that includes juxtamembranous p120, and γ- and 
β-catenin binding sites (4).
Predominantly expressed at the basolateral membrane of 
epithelial cells, where its function is primarily cell-cell adhesion, 
E-cadherin has been shown to be essential during morula 
compaction and the subsequent epithelial tissue organization, 
which is achieved through hemophilic interactions between 
cadherin molecules, first among adjacent cells (trans‑interaction) 
and then within the same cell by lateral association 
(cis-interaction) (5). Malignant epithelial cells undermine 
the function of E-cadherin in several ways, including gene 
mutations, epigenetic silencing by promoter hypermethylation, 
loss of heterozygosity, transcriptional silencing and microRNAs 
that regulate expression, transport and protein turnover at the 
cell surface (6-8).
Neural precursor cell-expressed developmentally 
downregulated 9 (NEDD9) protein is a member of the 
non-catalytic scaffolding proteins family (9), which also 
includes CASS1/BCAR1/p130Cas, CASS3/EFS/Sin and 
CASS4/HEPL. These proteins show the conservation of similar 
domain structures; an N-terminal Src homology 3 (SH3) domain 
that binds protein substrates (e.g., FAK, PYK2) and contains 
polyproline motifs, and a large substrate domain incorporating 
multiple YxxP motifs, which are phosphorylated by the Src 
family kinases to create binding sites for proteins with SH2 
domains. The serine-rich region likely folds into a 4-helix bundle 
and highly conserved carboxyl-terminal domain that mediates 
homo‑ and heterodimerization with CASS1/BCAR1/p130Cas. 
Although the protein is mainly cytoplasmic, small quantities 
are localized with centrosomes and the ciliary basal body. The 
signaling function of NEDD9 is integrin-dependent, regulated 
by the phosphorylation of serines, threonines and tyrosines 
in the structural domains. PP2A phosphatases are potential 
regulators of the NEDD9 phosphorylation status. NEDD9 
has a molecular weight of 93 kDa and oscillates between a 
faster migrating form of 105 kDa in G1/S cells and a slower 
migrating form of 115 kDa in G2/M cells. Previous studies 
have identified the crucial role of NEDD9 in the coordination 
of signaling cascades, contributing to changes in cell adhesion, 
migration, invasion and EMT (9,10). In normal human tissue, 
the highest level of NEDD9 is expressed in the lungs and 
kidneys, which are rich in immature lymphoid cells, and in the 
fetal brain prior to downregulation in the adult brain (10). Many 
cell lines, such as epithelial tumor-, melanoma-, lymphoma- 
and glioblastoma-derived cell lines, express an abundance of 
NEDD9.
Due to its pleotropic functions (cell adhesion, migration, 
invasion and EMT), the elevated expression of NEDD9 has 
emerged as a predictor of poor outcome, metastatic potential 
and chemoresistence in multiple cancer types (breast cancer, 
gastric cancer, glioblastoma, head and neck squamous cell 
carcinoma, hepatocellular carcinoma, non-small cell lung 
cancer, ovarian cancer, renal cancer, pancreatic ductal adeno-
carcinoma, prostate cancer and T-cell leukemia) (10-19). 
NEDD9 is a bona fide melanoma metastasis gene that enhances 
invasion in vitro and metastasis in vivo of both normal and 
transformed melanocytes (14). A growing body of preclinical 
data supports the theory that altered NEDD9 function is asso-
ciated with other human diseases, such as stroke, Alzheimer's 
disease and autosomal dominant polycystic kidney disease.
The data regarding NEDD9 and E-cadherin expression 
in CRC are insufficient. However, a study has shown that 
overexpression of NEDD9 positively mediates the canonical 
Wnt/ß-catenin signaling pathway in CRC and it also negatively 
regulates membrane expression of E-cadherin (3). There is 
also a paper in which NEDD9 is identified as differentially 
expressed gene, associated with cyclin D1, which can be a 
molecular target for the treatment of CRC, because it interacts 
with their corresponding anti-neoplastic drugs (20). Therefore, 
our study aimed to analyze the immunohistochemical 
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NEDD9 and E-cadherin expression in a tissue microarray of 
nonmetastatic and metastatic CRC, and to determine whether 
their expression is associated with the clinical behavior and 
prognosis of CRCs.
Patients and methods
Patient information. Following approval by the Ethical 
Committee of Clinical Hospital Center Sestre Milosrdnice 
(Zagreb, Croatia), a total of 40 pairs of formalin-fixed, 
paraffin‑embedded (FFPE) primary CRC and corresponding 
matched liver metastasis tissue specimens were retrieved 
from the tissue bank of the Ljudevit Jurak Department of 
Pathology and Cytology. The patients gave their written 
informed consent for the use of their biological materials and 
data in research. The patients had no history of the familial 
aggregation of CRC, had not been previously treated with 
chemo- or/and radiotherapy, and had undergone simultaneous 
colorectal and hepatic resection between January 1st, 2006 and 
December 31st, 2013. Tumor staging was performed according 
to the 7th edition of the TNM classification for CRC. The 
follow up deadline was December 31st, 2015. The survival 
time was calculated from the date of surgery to the follow up 
deadline, or the date of death. The clinicopathological features 
of patients are summarized in Table I.
Immunohistochemistry. Immunohistochemical analyses were 
performed by two board-certified pathologists who were 
blinded to the clinical data of the patients. Paraffin‑embedded 
tissue sections (thickness 3-5 µm) were deparaffinized for 
2 h at 60˚C and then washed with distilled water after two 
and three changes of xylene and ethanol, respectively. 
Immunohistochemical staining was performed using the 
microwave streptavidin immunoperoxidase (MSIP) protocol, 
and by use of the labelled streptavidin‑biotin (LSAB) method 
on a TechMate™ Horizon automated immunostainer (Dako; 
Agilent Technologies, Inc., Santa Clara, CA, USA) (11). 
Sections were incubated with rabbit anti-human NEDD9 poly-
clonal (dilution 1:100, cat. no. ab37161; Abcam, Cambridge, 
UK) and mouse anti‑human E‑cadherin monoclonal (dilu-
tion 1:50, clone NCH-38; Dako; Agilent Technologies, Inc.) 
antibodies overnight at 4˚C, followed by incubation with 
horseradish peroxidase-conjugated secondary goat anti-rabbit 
antibody (Abcam) for 1 h at room temperature. Sections were 
then washed with PBS and the antigen‑antibody complex was 
visualized.
The reactions were determined in epithelial tumor compo-
nents, as well as from the epithelial components of metastatic 
tumors in the LN and liver (Fig. 1). Positive reactions were 
determined at the site of strongest activity (‘hot spot’) under a 
magnification, x400 for a total of 1,000 tumor cells. The ‘hot 
spot’ was established following inspection of the whole section 
at a magnification of x40. The results for E‑cadherin were 
presented semi-quantitatively using an immunohistochemical 
staining index (ISI), obtained by multiplying the intensity of 
reaction with the percentage of cells with a positive reaction. 
The range of ISI was from 0 to 9: 0, represents no reaction, 
1-4 represents a low E-cadherin reaction, 5-9 represents a 
high E-cadherin reaction. The intensity of the reaction was 
scored as follows: 0, no reaction; 1, weak reaction; 2, moderate 
reaction; and 3, strong reaction. The percentage of immuno-
reactive tumor cells was scored as follows: 0, for no reaction; 
1, 0-10% of positive tumor cells; 2, >10-50% of positive tumor 
cells; and 3, >50% of positive tumor cells (21). The results for 
NEDD9 were presented semi-quantitatively and scored in the 
following way: 0, no reaction; 1, weak reaction in 0-10% of 
tumor cells; 2, moderate reaction in >10-25% of tumor cells; 
and 3, strong reaction in >25% of tumor cells (11).
Statistical analysis. The normality of data distribution was 
assessed with the Kolmogorov‑Smirnov test, and appropriate 
non-parametric tests were used in the following statistical 
analyses. Spearman's ρ and Kendal's τ‑b correlation coeffi-
cients for nominal-ordinal correlation were used to analyze 
associations between E-cadherin and NEDD9 expression in 
the primary tumor, LN and liver with other clinical variables. 
A log-rank (Mantel-Cox) test of the equality of survival 
distributions was performed for the expression of E-cadherin 
and NEDD9 in the primary tumor, LN and liver in relation 
Table I. Clinical description of the investigated sample 
(Dukes D, total n=40).
Parameter  n %
Sex
  Male 23 57.5
  Female 17 42.5
Localization of primary tumor
  Colon 28 70.0
  Rectosigmoid junction 2 5.0
  Rectum 10 25.0
T status    
  T1 0 0
  T2 3 7.5
  T3 34 85.0
  T4 3 7.5
N status    
  N0 or Nx 9 22.5
  N1 18 45.0
  N2 13 32.5
Surgical margins    
  Negative 39 97.5
  Positive 1 2.5
Microvascular invasion
  Absent 25 62.5
  Present 15 37.5
Perineural invasion
  Absent 28 70.0
  Present 12 30.0
Outcome
  Survived 18 45.0
  Succumbed 22 55.0
T, tumor; N, lymph node.
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to the survival outcome. The outcomes were illustrated with 
Kaplan‑Meier survival curves. P<0.05 was considered to indi-
cate a statistically significant difference. The data analysis 
software SPSS Statistics, version 23.0 (IBM Corp., Armonk, 
NY, USA) was used for statistical analyses and the production 
of graphical images.
Results
A clinical description of the investigated sample is shown in 
Table I. Of the patients, 57.5% were male. Median (interquar-
tile range, IQR) age was 64.0 (57.3-73.5) years. Of the tumors, 
70.0% were localized in the right colon. Median (IQR) tumor 
size was 50.0 (36.3-60.0) mm. Among the patients, 85.0% had 
T3 stage, and 22.5% had N0 or Nx stage. Microvascular inva-
sion was positive in 37.5% of patients, and PNI in 30.0% of 
patients. Death occurred in 55.0% of patients, with a median 
(IQR) survival time of 620.5 (164.3-964.8) days. The median 
(IQR) percentage of positive LN was 13.9% (0.0-44.1%).
The E-cadherin and NEDD9 expression scores in the 
investigated samples are shown in Table II. 87.5% of the 
patients had a strong expression of E-cadherin in the primary 
tumor, 67.7% in the LN, and 77.5% in the liver. Highly posi-
tive NEDD9 expression in the primary tumor was identified 
in 22.5% of patients, while 35.5% had highly positive NEDD9 
expression in the LN, and 30.0% in the liver.
The correlation coefficients for E‑cadherin and NEDD9 
expression in the primary tumor, LN and liver with clinical 
characteristics are shown in Table III. Significant positive 
correlation was noted between the percentage of positive LN 
with the ISI for E-cadherin in the LN (ρ=0.372; P=0.039) and 
with NEDD9 expression in LN (ρ=0.451; P=0.011), indicating 
that higher expression is significantly associated with a higher 
percentage of positive LN. Kaplan‑Meier survival curves with 
log-rank tests for the expression of E-cadherin and NEDD9 
in the primary tumor, LN and liver in relation to the survival 
outcome are shown in Fig. 2. There was no significant predic-
tion of mortality associated with the expression of E-cadherin 
and NEDD9 at any location, indicating that for this tumor 
stage (Dukes D), other prognostic markers are likely to be 
more clinically relevant.
Discussion
Left- and right-sided CRCs differ with respect to biology, 
epidemiology, pathology and clinical presentation. It is 
expected that most patients with synchronous liver metastases 
have right-sided CRC.
Various studies have shown controversial results regarding 
the expression levels of E-cadherin in CRC. Yun et al (22) 
studied stage III CRC, and found positive expression in 
98.3% of samples. Dorudi et al (23) found that 81.2% of 
well and moderately differentiated tumors expressed strong 
positivity for E-cadherin, while 85.7% of poorly differ-
entiated tumors were E-cadherin-negative. Three studies 
(Miladi-Abdennadher et al (24), Palaghia et al (25) and 
Elzagheid et al (26) identified a marginally lower expression 
(74.3, 67.69 and 59%, respectively). We attribute the results of 
Elzagheid et al (26) to the inclusion of all CRC stages in their 
study. In contrast to the aforementioned studies, Gu et al (27) 
identified that only 20% of patients with metastatic CRC had 
positive E-cadherin expression. The limitation of our study 
is reflected in the fact that we assessed only the membranous 
expression of E-cadherin. Elzagheid et al (28) assessed the 
cytoplasmic expression of E-cadherin. Tóth et al (29) used a 
scale based only on the percentage of immunopositive cells. 
Palaghia et al (25) used two scoring systems that were initially 
established for gastric carcinoma.
Our results show concordance with the results of 
Elzagheid et al (26), Khoursheed et al (30) and Roca et al (31), 
who reported that E-cadherin expression was not associated 
with tumor stage. Nevertheless, Ghadimi et al (32) reported a 
significant association between reduced E‑cadherin and lower 
tumor grade, but did not identify a clear correlation between 
the loss of E-cadherin expression and the depth of tumor 
infiltration into the intestinal wall. Kwak et al (33) showed 
that the reduced expression of E-cadherin was associated 
with advanced stage tumors (P=0.029), while Lugli et al (34) 
Figure 1. High intensity immunohistochemical expression of E‑cadherin in (A) the primary tumor, (B) LN metastasis and (C) liver metastasis. High intensity 
immunohistochemical expression of neuronal precursor cell-expressed developmentally downregulated 9 in (D) the primary tumor, (E) LN metastasis and 
(F) liver metastasis. Magnification, x200. LN, lymph node; E‑cadherin, epithelial cadherin.
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demonstrated that the loss of membranous E-cadherin was 
associated with a higher T-stage (P=0.03). Similar results were 
reported by Miladi-Abdennadher et al (24), who reported 
that E-cadherin expression was correlated with tumor size 
(P=0.02). Although the stage of the tumor was determined for 
every patient, the relatively small size of the group represented 
a limitation of the afore-mentioned study.
However, Roca et al (31) found no association between 
E-cadherin expression and LN metastasis. Similar to the 
present study, Kwak et al (33) demonstrated an association 
between E-cadherin expression and LN metastasis (P=0.004). 
Lugli et al (34) reported that in mismatch repair‑proficient 
CRC, the loss of membranous E-cadherin was independently 
associated with a higher N stage (P<0.0001). In MLH1- 
CRC, the loss of membranous E-cadherin was associated 
with a higher N stage (P=0.05) (34). Node-positive cancers 
exhibited significant loss of E‑cadherin (P<0.001) according 
to Karamitopoulou et al (35). Ozgüven et al (36) found that 
reduced E‑cadherin expression was significantly associated 
with LN metastasis (P=0.01). A borderline association of 
E-cadherin expression and LN metastasis (P=0.09) was 
reported by Elzagheid et al (26). Kim et al (37) reported that 
E-cadherin expression may serve as a predictive marker for 
tumor invasion and LN metastasis.
E-cadherin expression was increased in up to 40% of 
liver metastases, compared with only 17% of metastatic 
LNs that were studied by Ikeguchi et al (38), whose results 
are consistent with those of the present study. The results of 
Kim et al (39), who analyzed patients that had undergone cura-
tive surgery for primary CRC and liver metastases, showed 
that E-cadherin expression in the tumor center was greater 
than that of the tumor margin, in the primary tumor and liver 
metastases (P<0.001, P=0.006, respectively). A likely explana-
tion is the possibility that tumor cells regain epithelial features 
in distant metastases. Dorudi et al (23) and Mohri (40) postu-
lated that negative E-cadherin expression was associated with 
liver metastasis. Nanashima et al (41) reported that negative 
E-cadherin expression tended to be associated with a poor 
prognosis. Kaihara et al (42) reported that LN metastasis 
and the decreased expression of E-cadherin were associated 
with liver metastasis. Elzagheid et al (28) reported that the 
E-cadherin membranous (MI) and cytoplasmic index (CI) 
were significantly higher in liver metastases compared to other 
anatomic sites (MI, P=0.034; CI, P=0.022). Truant et al (43) 
demonstrated that the expression of E‑cadherin significantly 
increased in metastases compared with normal liver tissue. 
Gagliardi et al (44) compared liver metastases with their 
corresponding primary tumors, and found a complete loss of 
E-cadherin expression in 50% of liver metastases, while 86% 
of the primary tumors associated with the liver metastases 
exhibited strong expression.
A connection between survival rate and the reduced 
expression of E‑cadherin was found by Kwak et al (33) and 
Kang et al (45), but was without statistical significance in a 
multivariate analysis; Lee et al (46) identified that the aber-
rant expression of E-cadherin in the invasive margin was a 
significant and independent risk factor for disease‑free and 
overall survival in multivariate analysis, while Yun et al (22) 
reported that decreasing E-cadherin expression was associated 
with a poor outcome in terms of overall survival in univariate 
(P=0.016), but not multivariate (P=0.303, risk ratio=1.984, 
95% confidence interval=0.539-7.296), analysis (46). The 
present study did not identify any statistically significant asso-
ciation between the survival rate and E-cadherin expression. 
Regarding the controversial results of E-cadherin expression, it 
should be noted that in various papers that we have mentioned, 
the research procedures were performed using various mono-
clonal antibodies, devices (instruments), classifications, and 
scoring systems (cut-off values). Therefore, there are many 
points that could have affected the difference in the results.
Studies of the immunohistochemical expression of NEDD9 
in human tissue samples are few in the literature. Xia et al (47) 
found that NEDD9 expression is increased in ~50% of CRC 
samples, compared with normal colorectal tissue. Li et al (48) 
noted the high expression of NEDD9 in 68 of 92 CRC samples, 
compared with 12 of 92 in normal tissues (P<0.01). It was found 
that NEDD9 was significantly associated with an advanced 
TNM stage (P=0.014), pT grade (P=0.009), pN (P=0.013) and 
pM status (P=0.047). Patients with a higher NEDD9 expression 
had a significantly shorter overall survival rate (P<0.01) (48).
Table II. E-cadherin and NEDD9 expression in the investi-
gated sample (Dukes D, total n=40).
ISI n %
E-cadherin in primary tumor
  0 2 5.0
  1 3 7.5
  2 35 87.5
E-cadherin in lymph nodes
  0 4 12.9
  1 6 19.4
  2 21 67.7
E-cadherin in liver
  0 1 2.5
  1 8 20.0
  2 31 77.5
NEDD9 in primary tumor
  0 8 20.0
  1 9 22.5
  2 14 35.0
  3 9 22.5
NEDD9 in lymph nodes
  0 7 22.6
  1 5 16.1
  2 8 25.8
  3 11 35.5
NEDD9 in liver
  0 3 7.5
  1 11 27.5
  2 14 35.0
  3 12 30.0
ISI, immunohistochemical staining index; NEDD9, neuronal 
precursor cell expressed developmentally downregulated 9.
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Table III. Coefficients for the correlation between E‑cadherin and NEDD9 expression in the primary tumor, lymph nodes and 
liver with clinical characteristics.
 E-cadherin NEDD9
 --------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------
Expression of site Primary tumor Lymph nodes Liver Primary tumor Lymph nodes Liver
Age (years)
  ρ 0.245 -0.048 0.305 -0.084 -0.139 0.052
  P 0.127 0.799 0.055 0.605 0.457 0.748
  n 40 31 40 40 31 40
Tumor size (cm)
  ρ -0.166 -0.281 -0.265 -0.025 0.08 0.175
  P 0.305 0.126 0.098 0.88 0.669 0.281
  n 40 31 40 40 31 40
T status
  ρ  -0.191   0.047 0.299
  P  0.304   0.803 0.061
  n 40 31 40 40 31 40
N status
  ρ 0.263 0.345 0.084 0.106 0.261 0.195
  P 0.102 0.057 0.604 0.515 0.156 0.227




  n 40 31 40 40 31 40
Surgical margins
  τB 0.06 ‑0.334 0.086 ‑0.108 ‑0.255 0.015
  P 0.711 0.066 0.598 0.507 0.166 0.929
  n 40 31 40 40 31 40
Microvascular invasion
  ρ 0.292 -0.022 0.176 -0.053 -0.041 0.108
  P 0.067 0.907 0.278 0.743 0.825 0.508
  n 40 31 40 40 31 40
Perineural invasion
  ρ 0.07 0.041 0.225 0.039 0.192 -0.094
  P 0.668 0.826 0.163 0.81 0.3 0.563
  n 40 31 40 40 31 40
Positive lymph nodes (%)
  ρ 0.2 0.372 -0.016 0.026 0.451 0.175
  P 0.217 0.039a 0.922 0.872 0.011a 0.281
  n 40 31 40 40 31 40
Sex
  τB 0.177 0.249 0.107 0.129 0.207 0.217
  P 0.263 0.157 0.497 0.378 0.217 0.143
  n 40 31 40 40 31 40
Survival time (days)
  ρ -0.137 -0.075 -0.292 -0.035 -0.229 0.068
  P 0.398 0.688 0.067 0.829 0.215 0.676
  n 40 31 40 40 31 40
aP<0.05. ISI, immunohistochemical staining index; T, tumor; N, lymph node; NEDD9, neuronal precursor cell expressed developmentally 
downregulated 9; M, metastasis; ρ, Spearman's rank correlation coefficient; τB, Kendall's τ‑b correlation coefficient.
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The present study identified a strong expression of NEDD9 
in 22.5% of primary CRC tumors, 35.5% of LNs and 30% of 
liver metastases. As did Li et al (48), we found a significant 
positive correlation between positive LN and NEDD9 expres-
sion. The difference in the expression of NEDD9 was also 
noted in cell lines (primary cell line SW480, and LN meta-
static cell line SW620, derived from the same patient) (49). To 
the best of our knowledge, there are no published data on the 
expression of NEDD9 in CRC liver metastasis. The expression 
is similar to that of LN. Further studies of the expression of 
NEDD9 in liver metastases are needed. Potentially due to the 
small study cohort, no connection between the expression of 
NEDD9 in the primary tumor, LNs or liver metastases with 
survival rate was identified in the present study. Limitations of 
our study mostly arise from the small sample size. However, the 
registry of Croatian patients that had a resection of their CRC 
does not exist. Furthermore, there are no universally accepted 
guidelines for the treatment of CRC, i.e., a similar case will 
be treated rather differently in various institutions. This situ-
ation poses unsurmountable challenges for the accruement 
of a larger Dukes D patients' group. Since 2014, the EGFR 
testing has become a standard part of pathological reports. If 
we were performing the research now, we would include the 
results of EGFR as a factor determining the sampling of our 
groups. Clinical significance/relevance lies in the possibility 
of an improved distinction among patients who will experi-
ence more benefits of anti-EGFR therapy. Similar studies 
about the expression of E‑cadherin and benefit of anti‑EGFR 
therapy were published in settings of patients with lung adeno-
carcinoma (50,51). However, the patients included from 2014 
still would not have a sufficient follow‑up data at this point. 
Due to our objectively limited resources and the impossibility 
to use CEA-controlled oncolytic adenovirus (it is not available 
in Croatia), CEA was not used, although we recognize it as 
‘one of the most important factors’. Additional limitations to 
our study arise from the absence of data on E-cadherin and 
NEDD9 expression in CRC cell lines and animal models of 
CRC. In the future diagnostic procedures, if the equipment, 
samples, and experienced, professional staff would be provided 
to our institution, we intend to use this method (52).
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